Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATYR 
aTyr Pharma, Inc. (ATYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ATYR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4
1 Year Target Price $4
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.91% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.64M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 11 | Beta 0.79 | 52 Weeks Range 0.68 - 7.29 | Updated Date 10/14/2025 |
52 Weeks Range 0.68 - 7.29 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.2% | Return on Equity (TTM) -85.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1892711 | Price to Sales(TTM) 1147.59 |
Enterprise Value 1892711 | Price to Sales(TTM) 1147.59 | ||
Enterprise Value to Revenue 132.17 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 97986634 | Shares Floating 95550686 |
Shares Outstanding 97986634 | Shares Floating 95550686 | ||
Percent Insiders 1.43 | Percent Institutions 65.03 |
Upturn AI SWOT
aTyr Pharma, Inc.
Company Overview
History and Background
aTyr Pharma, Inc., founded in 2003, is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. Initially focused on tRNA synthetase biology, it has evolved to address unmet medical needs in severe immune-mediated diseases.
Core Business Areas
- Drug Development: Focused on developing novel therapeutics targeting immune-mediated diseases. This includes researching, developing, and clinical testing of potential drug candidates.
- Research and Discovery: Identifying and validating new biological pathways and targets for therapeutic intervention, primarily leveraging its understanding of tRNA synthetase biology and related mechanisms.
Leadership and Structure
The company has a management team consisting of a CEO, CFO, CSO, and other key executives. The organizational structure includes departments for research and development, clinical operations, finance, and administration. Board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- Efcogamod: aTyr Pharma's lead clinical program, Efcogamod, is a selective modulator of Neuropilin-2 (NRP2). It is currently in Phase 3 development for pulmonary sarcoidosis. There are no direct competitors for Efcogamod in pulmonary sarcoidosis, however, traditional treatments such as corticosteroids exist. The total addressable population could reach hundreds of thousands globally.
- Preclinical Programs: aTyr Pharma has a portfolio of preclinical programs focused on modulating immune responses in various disease areas. Revenue is not generated from these programs at this stage. Competition comes from pharmaceutical companies with similar preclinical programs in the immuno-oncology and inflammatory disease space.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for immune-mediated disease therapies is large and growing, driven by increasing prevalence of autoimmune and inflammatory conditions.
Positioning
aTyr Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-mediated diseases. Its competitive advantage lies in its expertise in tRNA synthetase biology and its novel approach to modulating immune responses through Neuropilin-2.
Total Addressable Market (TAM)
The total addressable market for immune-mediated disease therapies is estimated to be in the billions of dollars annually. aTyr Pharma is positioned to capture a portion of this market with its Efcogamod program and pipeline of preclinical candidates.
Upturn SWOT Analysis
Strengths
- Novel biological target (Neuropilin-2)
- Lead clinical program (Efcogamod) in Phase 3
- Strong scientific expertise in tRNA synthetase biology
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on single lead program
- High risk associated with drug development
- No currently marketed products
Opportunities
- Successful clinical trial results for Efcogamod
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through research and development
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- JAZZ
- SRPT
- VRTX
Competitive Landscape
aTyr Pharma faces competition from larger pharmaceutical companies with established pipelines and greater financial resources. Its competitive advantage lies in its novel biological target and its focused approach to developing therapies for immune-mediated diseases.
Growth Trajectory and Initiatives
Historical Growth: Insufficient information to provide accurate data. Review of recent financial statements is necessary to complete.
Future Projections: Future growth is heavily reliant on the successful development and commercialization of Efcogamod. Analyst estimates vary depending on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Focus on advancing Efcogamod through Phase 3 clinical trials, expanding preclinical pipeline, and seeking partnerships for further development.
Summary
aTyr Pharma is a clinical-stage biopharmaceutical company with a novel target in Neuropilin-2 and a lead program, Efcogamod, in Phase 3 for pulmonary sarcoidosis. The company's success hinges on the clinical trial results and regulatory approval of Efcogamod, as well as future strategic partnerships. Key concerns include limited financial resources and dependence on a single lead program, creating high risk. Securing additional funding or partnerships will be vital for their growth and success, and the successful outcome of Efcogamodu2019s clinical trial will be crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- aTyr Pharma's website
- SEC filings
- Company press releases
- Analyst reports
- Other publicly available information
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About aTyr Pharma, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-05-07 | President, CEO & Director Dr. Sanjay S. Shukla M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://atyrpharma.com |
Full time employees 56 | Website https://atyrpharma.com | ||
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.